Probiodrug Licenses the TBA 2.1 Transgenic Alzheimer’s Disease Mouse Model to QPS Austria Neuropharmacology
Probiodrug to attend and present at US Life Science Conferences
Attendance at key conferences during September 2015
HALLE/SAALE, Germany, 03 September 2015 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that Dr Hendrik Liebers, Chief Financial Officer of Probiodrug, is scheduled to attend and present at the following events:
(1) 3rd European Neurotech Investing and Partnering Conference
9th, 10th September 2015, Grand Hotel Kempinski, Geneva, Switzerland
Dr Hendrik Liebers, CFO, to present on Wednesday 9th September, 10.30 CET
Dr Liebers will give an overview of the Company and its key programmes at the Treatments for Alzheimer’s and Cognitive Disorders Panel session. The European Neurotech Investing and Partnering Conference is a global forum where investors, executives, entrepreneurs, scientists and others involved in the development of new treatments and diagnostics for the brain and nervous system come together to shape the future of their organization and the industry.
(2) Goldman Sachs Biotech and Emerging Pharma Symposium
11th September 2015, Goldman Sachs, 120 Fleet Street, London, UK
Dr Hendrik Liebers, CFO, will be attending the conference on Friday 11th September
Probiodrug will be hosting investor meetings at the event. This is the second Biotech and Emerging Pharma Symposium held by Goldman Sachs in London.
(3) 15th Annual Biotech in Europe Forum for Global Partnering & Investment
29th, 30th September 2015, Congress Centre, Basel, Switzerland
Dr Hendrik Liebers, CFO, to present on Tuesday 29th September, 12.30 CET, Room Lima
Dr Liebers to also participate in the CNS & Pain panel session on Tuesday 29th September, 16.05 CET
Dr Liebers will give an overview of the Company and its key programmes and will also participate in the CNS & Pain panel. The 15th Annual Biotech in Europe Forum for Global Partnering & Investment draws together an exciting cross-section of early-stage/pre-IPO, late-stage and public companies with leading investors, analysts, money managers and pharma licensing executives.
###
For more information please contact:
Probiodrug
Dr Konrad Glund, CEO
Email: contact@probiodrug.de
Hume Brophy
Mary Clark, Supriya Mathur, Alexia Faure
Tel: +44 (0) 203 440 5653
Email: probiodrug@humebrophy.com
Notes to Editors:
About Probiodrug AG
Headquartered in Halle, Germany, Probiodrug AG (Euronext Amsterdam: PBD) is a biopharmaceutical company focused on the development of new therapeutic products for the treatment of Alzheimer’s disease.
Founded in 1997, the company successfully developed a novel therapeutic concept for diabetes – the DP4 inhibitors – which provided the basis for a novel class of antidiabetics – the gliptins. Its core capabilities are based on its long-standing expertise in the elucidation of the structure and function of enzymes involved in the modification of proteins and peptides, which play a central role in pathological conditions.
Today Probiodrug’s aim is to become a leading company in the development of Alzheimer’s disease treatments and to thereby provide a better life for Alzheimer’s disease patients. It has identified a new therapeutic concept linked to disease initiation and progression. The development approaches are targeting pyroglutamate-Abeta (pGlu-Abeta) as a therapeutic strategy to fight Alzheimer’s disease. The Company has medical use and composition of matter patents related to the inhibition of Glutaminyl Cyclase (QC) and anti-pGlu-Abeta- specific monoclonal antibodies, providing it, in the Company’s view, with a leading position in this field of research.
About Alzheimer’s disease
Alzheimer’s disease is a neurological disorder, which is the most common form of dementia, and ultimately leads to death. Because Alzheimer’s disease cannot be cured and is degenerative, the affected patients must increasingly rely on others for assistance. Today, 44 million people worldwide currently live with the condition and this number is expected to almost double by 2030 and to more than triple by 2050 to over 132 million. Alzheimer’s also has an estimated, global societal cost of over $600 billion (World Alzheimer Report 2014).
Forward Looking Statements
Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgment of Probiodrug AG as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.